A clotbusting drug commonly used to treat ischemic stroke interacts negatively with a promising anti-inflammatory treatment (anakinra), underscoring the need to test new stroke therapies alongside existing standard care. According to The University of Manchester–led study on mice, published in Stroke, the timing of anakinra must be adjusted to avoid reducing the benefits of the clot-busting therapy known as tissue plasminogen activator (tPA).
This article was originally published on MedicalXpress.com
